TY  - JOUR
AU  - Vitalle, Joana
AU  - Zenarruzabeitia, Olatz
AU  - Terren, Iñigo
AU  - Plana, Montserrat
AU  - Guardo, Alberto C
AU  - Leal, Lorna
AU  - Peña, Jose
AU  - Garcia, Felipe
AU  - Borrego, Francisco
PY  - 2017
DO  - 10.3389/fimmu.2017.00836
SN  - 1664-3224
UR  - http://hdl.handle.net/10668/11486
T2  - Frontiers in immunology
AB  - A modified vaccinia Ankara-based HIV-1 vaccine clade B (MVA-B) has been tested for safety and immunogenicity in low-risk human immunodeficiency virus (HIV)-uninfected individuals and as a therapeutic vaccine in HIV-1-infected individuals on combined...
LA  - en
PB  - Frontiers Research Foundation
KW  - CD300
KW  - CD300c
KW  - CD300f
KW  - HIV-1 vaccine
KW  - Human immunodeficiency virus
KW  - Lipopolysaccharide
KW  - Monocytes
KW  - Therapeutic vaccine
KW  - HIV infections
KW  - Lipopolysaccharides
KW  - Vaccinia
KW  - Monocytes
KW  - Treatment interruption
KW  - Virus diseases
KW  - HIV seropositivity
TI  - Monocytes Phenotype and Cytokine Production in Human Immunodeficiency Virus-1 Infected Patients Receiving a Modified Vaccinia Ankara-Based HIV-1 Vaccine: Relationship to CD300 Molecules Expression.
TY  - research article
VL  - 8
ER  -